We chose the Web of Science (WOS) Core Collection as the search platform for our publications, searching for topics such as “potassium competitive acid blocker”, “Vonoprazan”, “tegoprazan”, etc. The specific search strategy was: (TS=(potassium competitive acid blocker) OR TS=(vonoprazan) OR TS=(tegoprazan) OR TS=(revaprazan) OR TS=(keverprazan) OR TS=(Soraprazan) OR TS=(Fexuprazan) OR TS=(Linaprazan) OR TS=(Zastaprazan)). The search scope for literature is from the establishment of the database until 30 June 2024.

We established relevant standards for the inclusion and exclusion of searched literature. Inclusion criteria: English publications related to the treatment of ARDs with P-CABs, including articles and review articles. Exclusion criteria: 1) Literature unrelated to the above topic (The research scope or theme of these publications is not related to the treatment of ARDs with P-CABs); 2) Conference abstracts, letters, and other types of literature; 3) The language of the publication is not English.

Two researchers independently conducted literature screening and decided that a third party would make a decision at any time. For the included literature, we set the record content as “full record and cited references”, exported them in plain text file format for CiteSpace analysis, and exported them in tab delimited file format for VOSviewer analysis.

We used the citation analysis function provided by the WOS platform to obtain publication volume and citation data. By exporting the data, we analyzed the publication and citation trends of the included literature based on Microsoft Excel. For tab delimited file, they can be directly imported into VOSviewer 1.6.19 software. For plain text files, we rename all downloaded documents to “download_**.txt” and saved them in the “input” folder. We used CiteSpace 6.3.R1 software to convert the data for subsequent analysis.

Using Citespace 6.3.R1, the converted data was analyzed for author, institution, country, keyword co-occurrence, keyword clustering, keyword burst and citations. We calculated frequency and centrality of nodes in various indicators through software, where nodes represent authors, countries, institutions, keywords, and references in different indicator. The main parameter settings were as follows: set the time slice to 1 year, the node type to single node, the k value in g-index was 25. When conducting keyword occurrence and reference analysis, “Pathfinder” and “Pruning sliced networks” were selected from the “Pruning” option to prune the network graph. In addition, to ensure meaningful results, we merged keywords with the same meaning, mainly by defining the keyword with the highest frequency as the primary keyword and the other keywords with the same meaning as secondary keywords, and adding the secondary keywords to the primary keywords. The list of merged keywords can be found in Supplementary Table S1.

In VOSviewer 1.6.19, we constructed co-occurrence graphs with author, country and institution frequency thresholds of 5. We selected the counting method as full record and also generated graphs for network visualization and density visualization under different indicators.

This study initially searched for 1086 publications; After setting the included literature types as “article” and “review article”, there were still 730 publications left; Subsequently, 727 articles were left after setting the language type to English. After reading the abstract, 272 articles unrelated to the topic were excluded, and finally 455 articles were included. The annual publication volume and citation results are shown in Figure 1. After analysis, it can be concluded that in terms of publication volume, the earliest publication related to the topic was published in 2004, followed by a significant increase in publication volume in 2016 and reaching its peak in 2023 (The number of publications was 94). Although we only counted publications in the first half of 2024, their publication volume in the first half of the year also reached 53. It is speculated that the publication volume in 2024 will further increase compared to the previous year. The total citation count of the included publications was 8,561 times. There was also a similar trend in terms of citations: the number of citations continued to increase, and reached its peak in 2023 (The number of citations was 1913 times). Based on the above conclusions, we can see that the number of publications and citations related to the study of P-CABs in ARDs are constantly increasing, indicating the growing attention and popularity of this research field.

In the co-occurrence analysis of authors, we used VOSviewer to screen authors with a publication threshold of 5. Among 2,528 authors, a total of 94 authors were selected. The relevant visualization graph is shown in Figure 2, and the list of the top nine authors in terms of publication volume is shown in Table 1. In addition, we constructed a time zone map of author co-occurrence using Citespace, which allows us to directly observe the publication years and collaboration relationships of all authors. Detailed information can be found in Supplementary Figure S1. The top nine authors in terms of publication volume were all from South Korea and Japan, with relatively low centrality. The results of network visualization and overlay visualization (Figures 2A, B) showed that the author collaboration network was generally scattered and formed multiple small groups represented by authors of high publication volume. Considering that the small groups formed by authors with high publication rankings have been engaged in extensive research in related fields, and their publications can to some extent reflect the research trends in this field, we classified and analyzed small groups based on the top nine authors in terms of publication volume.

Firstly, the collaborative network formed by the research group represented by four researchers from South Korea (Geun Seog Song, Bongtae Kim, SeungHwan Lee, In-Jin Jang) was relatively close. Among the four authors, Geun Seog Song had the highest publication volume (14 articles), followed by Bongtae Kim (13 articles). The time span of the four scholars’ publications is from 2018 to 2023, mainly focusing on the pharmacokinetics, pharmacodynamics, and safety of P-CABs, with the main research object being tegoprazan. As time goes by, researchers’ research directions are constantly changing, and the relevant results mainly involve the combination of tegoprazan and antibiotics (Ghim et al., 2021; Jeon et al., 2021; Huh et al., 2022), the interaction between tegoprazan and food (Han et al., 2021; Yoon et al., 2021), the interaction between tegoprazan and CYP2C19 (Yang et al., 2023), the interaction with NSAIDs (Moon et al., 2022) and effect of acid suppression at night (Han et al., 2023; Yang et al., 2022). Overall, tegoprazan can overcome various pharmacokinetic barriers of previous PPIs administration and can provide a new option for the treatment of ARDs. It is worth noting that in 2023, some scholars explored the carcinogenic potential of P-CABs for long-term acid suppression, and the results showed that tegoprazan induced gastric enterochromaffin-like cell tumors in SD rats (Kim et al., 2023). At the same time, researchers are also working on the development of new formulations of P-CABs, such as the pharmacokinetic differences between the new orally disintegrating tablet of tegoprazan and the conventional tablet (Lee et al., 2023) (The results showed the equivalence of the new formulation), and the pharmacokinetic and pharmacodynamic differences between the delayed-release formulations of tegoprazan and the immediate-release formulation (The results indicated a breakthrough in gastric acid suppression with the delayed-release formulations) (Park et al., 2023).

In addition, among the other five scholars from Japan, Nobuhiro Inatomi had the highest publication volume and the earliest publication time. In 2010, this scholar studied the acid suppressive effect of vonoprazan (TAK 438) in animal models (Hori, 2010) and conducted a series of preclinical studies between 2011–2012 (Hori et al., 2011; Nishida et al., 2012). In 2016, Nobuhiro Inatomi collaborated with Yuuichi Sakurai to systematically elucidate the pharmacological properties of vonoprazan and its potential applications in ARDs (Inatomi et al., 2016; Otake et al., 2016). Yuuichi Sakurai et al. also evaluated the pharmacokinetic differences of the interaction between vonoprazan and other drugs (NSAIDs (Sakurai et al., 2017) or antibiotics (Sakurai et al., 2016)) between 2016 and 2017 to assess the feasibility of P-CABs as a treatment option for gastrointestinal adverse reactions caused by NSAIDs or Helicobacter pylori infection. In 2024, the latest study by this scholar evaluated the efficacy of vonoprazan compared to lansoprazole in maintenance therapy for healed erosive esophagitis patients in Asia. The results showed that vonoprazan was not inferior to lansoprazole in preventing the recurrence of erosive esophagitis (Xiao et al., 2024). The articles published by Katsuhiko Iwakiri are all related to gastroesophageal reflux disease, including erosive reflux disease and non-erosive reflux disease. From 2017 to 2019, highly cited research results showed that vonoprazan had more advantages than lansoprazole in the maintenance treatment of healed erosive esophagitis (Ashida et al., 2018), and vonoprazan still had good efficacy in the initial and maintenance treatment of PPIs resistant-reflux esophagitis (Hoshino et al., 2017; Iwakiri et al., 2017; Tanabe et al., 2019). In addition, researchers also paid attention to the resistance mechanism and clinical symptoms of vonoprazan in the treatment of non-erosive reflux disease in the later stage of the study (Kawami et al., 2018; Hoshikawa et al., 2021). Satoshi Shinozaki and Alan Kawarai Lefor had a relatively close cooperative relationship. In the early stages of the study, The research team represented by two scholars focused on the difference in therapeutic efficacy of vonoprazan compared to PPIs for Helicobacter pylori infection (Shinozaki et al., 2016; Shinozaki et al., 2018a) (a highly cited evidence-based study showed that the vonoprazan treatment regimen had a significant advantage over PPIs based regimens in second-line Helicobacter pylori eradication therapy (Shinozaki et al., 2021)) and the efficacy of vonoprazan in treating gastroesophageal reflux disease (the results showed that vonoprazan could significantly alleviate patients’ gastrointestinal symptoms (Shinozaki et al., 2017; Shinozaki et al., 2018b)). In the later stages of the study, researchers focused on the effects of vonoprazan on serum gastrin levels (Shinozaki et al., 2022a) and gastric morphology. It is worth noting that the results showed that long-term vonoprazan use increased the prevalence of fundic gland polyps, gastric hyperplastic polyps and cobblestone-like mucosa (Shinozaki et al., 2022b). In addition, they explored the therapeutic effect of vonoprazan on functional dyspepsia without heartburn and preliminarily confirmed the short-term efficacy of vonoprazan, similar to that of acotiamide (Shinozaki et al., 2023).

In summary, authors with high publication volumes are concentrated in South Korea and Japan. Although research is scattered, the feasibility of adding P-CABs to ARDs treatment regimens and efficacy for different ARDs are the main focuses. At the same time, researchers also pay attention to the short-term and long-term effects of gastric acid suppression caused by P-CABs treatment.

In the co-occurrence analysis of countries, we used VOSviewer to filter countries with a publication threshold of 5. Out of 38 countries, a total of 13 were selected. The relevant visualization graphs are shown in Figures 3A, B, and the top five countries in terms of publication volume are shown in Table 2. We also used CiteSpace to generate a time zone map of country co-occurrence, as detailed in Supplementary Figure S2. Among all countries, the top three in frequency are Japan (210 articles), China (117 articles), and South Korea (77 articles), while the top three in centrality are the United States (0.93), Japan (0.17), and Italy (0.14), indicating that Japan had more output and there was stronger cooperation between the United States and other countries. As the country with the highest number of publications, Japan has reached 12 articles in the first half of 2024. The latest research results focued on the effectiveness of P-CABs in preventing gastrointestinal bleeding, but were more specific. For example, they compared the incidence of rebleeding after gastrointestinal bleeding prevention between P-CABs and PPIs, and compared the effectiveness of P-CABs or PPIs in preventing gastrointestinal bleeding after percutaneous coronary intervention in patients with ischemic heart disease under real-world conditions (Abe et al., 2024; Sasaki et al., 2024). Meanwhile, Japanese researchers have also begun to pay attention to the adverse events of P-CABs and have explored them in clinical studies. They studied the correlation between long-term use of P-CABs and cancer (Arai et al., 2024), as well as treatment strategies for microbiota dysbiosis caused by P-CABs (for example, 1-kestose, a prebiotic, prevented the microbiome changes caused by vonoprazan (Furune et al., 2024)). In 2024, scholars from South Korea and Japan conducted quadruple therapy treatments for Helicobacter pylori infection, including one P-CAB, two antibiotics, and one bismuth agent (Tungtrongchitr et al., 2024; Cho, 2024). Although the subjects studied are different (tegoprazan in South Korea and vonoprazan in Japan), it can be inferred that scholars are still searching for the best combination therapy for treating Helicobacter pylori infection.

In the co-occurrence analysis of institutions, we used VOSviewer to filter institutions with a threshold of five for publication volume. Out of 752 institutions, a total of 69 institutions were selected. The relevant visualization graphs are shown in Figures 3C, D. The top ten institutions in terms of publication volume are all from South Korea and Japan, as shown in Table 3. We also used CiteSpace to generate a national co-occurrence time zone map, as detailed in Supplementary Figure S3. Among all institutions, the top three in terms of frequency are Takeda Pharmaceutical Company Ltd. (49 articles), Seoul National University (28 articles), and Catholic University of Korea (15 articles), while the top three in terms of centrality are Takeda Pharmaceutical Company Ltd. (0.35), Hyogo Medical University (0.14), and Chinese Academy of Medical Sciences Peking Union Medical College (0.13). Takeda Pharmaceutical Company Limited is the manufacturer of vonoprazan fumarate tablets (trade name: Vocnti). In 2010, the company published an article introducing the pharmacological effects and basic research results of vonoprazan. Subsequently, when vonoprazan was launched in 2015, the company’s publication volume increased and reached its peak in 2017. The most cited article of the company was published in 2015, which evaluated the efficacy of vonoprazan as a component of first-line and second-line regimens for eradicating Helicobacter pylori and demonstrated its noninferiority. In the past 2 years, scholars from the institution have also focused on the safety of using vonoprazan for the treatment of ARDs after its launch. For example, the safety of using vonoprazan for long-term maintenance treatment of erosive esophagitis (Haruma et al., 2023) and the safety of long-term use of vonoprazan in preventing gastrointestinal ulcer recurrence in patients using NSAIDs (Kawai et al., 2023) have been studied, and the results showed that vonoprazan had good safety. At the same time, researchers conducted pharmacokinetic studies on the use of a quadruple therapy containing vonoprazan and bismuth agents in Chinese patients with Helicobacter pylori infection, demonstrating the safety of this therapy (Miao et al., 2023).

After data cleaning of the keywords, we conducted co-occurrence analysis, cluster analysis, and burst analysis using Citespace. The co-occurrence analysis chart is shown in Figure 4, and the top 30 keywords in terms of frequency are listed in Table 4. In the co-occurrence chart, a total of 981 nodes and 4,917 lines were obtained. Most nodes have low centrality, but the contours of four keyword nodes appear purple (representing centrality greater than 0.1), with centrality of 0.11, namely, “management”, “pharmacokinetics” “secretion” and “risk”. The most frequent keywords can be roughly divided into the following categories: 1) P-CAB, with the most frequent keyword being “vonoprazan” (154). This keyword first appeared in 2014, but its frequency is high, indicating that the drug received high attention during its development and after its launch. 2) ARD, with high-frequency disease keywords including Helicobacter pylori infection, gastroesophageal reflux disease, peptic ulcer and erosive esophagitis. In addition, there are multiple related keywords involved in Helicobacter pylori infection, including eradication of Helicobacter pylori, antibiotic treatment (such as clarithromycin), and resistance issues. 3) PPI, among which high-frequency keywords include “lansoprazole” (135), “esomeprazole” (97), “omeprazole” (61), etc. 4) Drug treatment plans, such as first-line therapy, dual therapy, and triple therapy. 5) Clinical research methods, such as randomized controlled trial, meta-analysis, etc. In addition, “gastric cancer” (33) is also a top 30 keyword, which first appeared in 2016, and research on this topic includes multiple aspects. Several studies evaluated the efficacy of vonoprazan compared to PPIs in the treatment of gastric ulcers after endoscopic submucosal dissection for gastric cancer, and the results showed that vonoprazan has a comparable effect to PPIs (Tsuchiya et al., 2017; Hirai et al., 2018). It is worth noting that a study in 2024 evaluated the differences in the long-term risk of gastric cancer among patients treated with Helicobacter pylori eradication regimens containing different acid inhibitors. The results showed that long-term or high-dose use of P-CABs was associated with an increased risk of gastric cancer compared to H2 receptor antagonists (Arai et al., 2024). Based on the content classified by the above keywords, it can be inferred that in the early stages of research, the study of P-CABs focused on drug mechanism, pharmacodynamics and pharmacokinetics. Since the representative drug was put into clinical application, research tended to compare P-CABs with traditional treatment regimens in ARDs, and a large number of clinical trials have been conducted to explore their efficacy and safety. In addition, since the keywords listed in Table 4 all appeared before 2017, we also selected the keywords with the highest frequency ranking and a frequency threshold of 10 (Supplementary Table S2) each year after 2017 for analysis. These keywords appeared later and had a higher frequency, which can help us understand the research trends in recent years. The keyword “risk” (19) has a high centrality, and research related to this topic includes multiple aspects. We have noticed some new findings in highly cited articles, such as the impact of P-CAB use on gut microbiota (there is still controversy over whether vonoprazan affects indomethacin-induced small intestinal injury by altering the gut microbiome) (Nadatani et al., 2019; Li et al., 2022), the safety of P-CAB in children (Kusano et al., 2018), and the gastric changes caused by P-CAB use (Shinozaki et al., 2022b). In addition, studies have found a significant correlation between the use of vonoprazan and Clostridium difficile infection (Watanabe et al., 2021). The keyword “network meta-analysis” (11) first appeared in 2019, and in the past 2 years, the number of related publications has increased rapidly, reaching seven articles. Researchers are enthusiastic about using this method to compare the efficacy of multiple drug regimens in treating ARDs (Rokkas et al., 2021; Miwa et al., 2019; Gao et al., 2020). The keyword “quadruple therapy” (14) first appeared in 2020, and in the past 2 years, the number of related research publications has reached 9. The main research focus is on the efficacy of related treatment regimens for Helicobacter pylori infection (Lu et al., 2023; Yan et al., 2024).

We used the log-likelihood ratio (LLR) method to cluster keywords and further summarize the exploration directions of researchers. A total of 17 clustered words were obtained and ranked according to the number of keywords covered, numbered from # 0 to # 16 in sequence. The clustering diagram of keywords and the timeline diagram of clustered keywords are shown in Figure 5. The line colors in the timeline graph (Figure 5B) correspond to the filling colors of the contours of each cluster word in the clustering graph (Figure 5A). Nodes on each timeline represent the order in which keywords appear over time, and lines represent the relationships between each keyword. The average Modularity Q value is 0.6262 (>0.3), and the average Silhouette S value is 0.8410 (>0.5), indicating that the clustering is reasonable (Sabé et al., 2024).

In the clustering keywords, #1 (proton pump inhibitors, average year: 2020), #10 (gelatine microsphere, average year: 2020), #11 (dual therapy, average year: 2019), #14 (potassium channel blocker, average year: 2007), and #16 (antiulcer agents, average year: 2011) can be classified as therapeutic drugs or treatment regimens. It can be inferred that researchers have been paying attention to anti-ulcer drugs for a long time, and have been focusing on the development of acid inhibitors targeting potassium channels for an earlier period in the past. Around 2015, research including PPIs began to rise and continue to this day, and the comparative results of the two types of drugs continued to receive attention. In addition, researchers have also focused on the development of new formulations, such as gelatin microspheres loaded with revaprazan, which effectively improve the solubility and bioavailability of P-CABs (Kim et al., 2018). In terms of treatment regimens, the topic of dual therapy is relatively late on the timeline, with an average year of 2019. In the past 2 years of research, dual therapy has also received attention in relation to microbial dysbiosis and the use of probiotics (Peng et al., 2023). #0 (Helicobacter pylori, average year: 2019), #7 (gastrointestinal bleeding, average year: 2021), #9 (Helicobactor pylori, average year: 2017), and #15 (supragastric belching, average year: 2020) can be classified as diseases or diagnoses. Helicobacter pylori infection is a disease that researchers have been continuously concerned about, and the themes surrounding it cannot be separated from infection eradication, drug-resistant treatment and evaluation of treatment plan. PPIs have been used in the past to prevent gastrointestinal bleeding caused by various reasons. In recent years, researchers have also evaluated the feasibility of P-CABs as an intervention in the treatment of cardiovascular and cerebrovascular diseases (Sasaki et al., 2024; Ishii et al., 2023). In addition, as one of the clustering words, supragastric belching is mainly related to vonoprazan-refractory reflux symptoms. Researchers were also concerned about the incidence and mechanisms of behavioral disorders, including supragastric belching and rumination syndrome, in this group of patients (Hoshikawa et al., 2021).

In addition to the above clustering words, We also obtained eight other clustered words. Some of the clustering words, such as # 2 (suppression), # 6 (management), # 8 (impact), and # 12 (clinical trial), represent general themes. We speculated that they are related to acid inhibition of ARDs, treatment of P-CABs, and disease management, so we did not analyze them. We also obtained some clear and representative clustering words, such as #3 (endoscopic submucosal dissection, average year: 2018), #4 (gut microbiome, average year: 2019), #5 (cytochrome p450, average year: 2018) and #13 (24 h mii-ph: 2020). Represented by articles with high citation frequency, researchers evaluated the efficacy of vonoprazan in treating gastric ulcers after endoscopic submucosal dissection and revealed that its efficacy is not inferior to PPIs (Hamada et al., 2019; Maruoka et al., 2017), evaluated the effect of vonoprazan combined with antibiotic therapy (Hu et al., 2022) on the gut microbiota of patients with Helicobacter pylori infection and the value of combined probiotic therapy (Kakiuchi et al., 2020), and evaluated the in vitro and in vivo interactions (Wang et al., 2020) of vonoprazan with other drugs based on cytochrome P450 (such as voriconazole (Shen et al., 2020), proguanil (Funakoshi et al., 2019), etc.). Our clustering analysis also included the clustering term “24-h mii ph”. 24-h multi-channel intraluminal impedance pH, abbreviated as “24-h mii ph”, is a diagnostic criterion for laryngopharyngeal reflux. Previously, this disease is usually treated with PPIs, but in 2024, researchers have begun to explore the effects of P-CABs on the pharyngeal microbiota composition of such patients (Zheng et al., 2024).

Burst analysis can reflect the activity level of certain keywords during a certain period of time, and thus infer the research frontiers and hotspots in different time periods. We chose a γ value of 1.0, a minimum duration of 2 years for keywords, and default values for other parameters to obtain 10 burst keywords (Table 5, where red and blue bars represent keywords bursts and disappearances, respectively). In terms of drug treatment mechanism research, three hot keywords appeared in 2007 and disappeared before 2016. During this period, research focused on exploring the pharmacological effects and activities of P-CABs. Some highly cited studies investigated the affinity and mechanism of action of P-CABs with H, K-ATPase, compared the activity of drugs in different acidic environments (Scott et al., 2015; Luo et al., 2014), and compared the acid suppressive ability of vonoprazan and PPIs in animal models (Hori, 2010; Arikawa et al., 2012). Between 2014 and 2017, “vonoprazan”, “tolerance”, and “pharmacodynamics” became hot keywords, followed by “Japan” from 2016 to 2019. During this period, vonoprazan had been approved and put into clinical use, undoubtedly generating a large number of high-level research results. In terms of pharmacodynamics and tolerability, the most notable studies during this period were the efficacy and tolerability of vonoprazan compared to lansoprazole in gastrointestinal ulcers (Miwa et al., 2017) and erosive esophagitis (Ashida et al., 2015). The results showed that vonoprazan was not inferior to lansoprazole and had good tolerability. In addition, high-quality studies conducted between 2017 and 2018 had shown that vonoprazan had non inferiority compared to lansoprazole in the maintenance treatment of erosive esophagitis (Ashida et al., 2018). For patients with erosive esophagitis who were ineffective with PPIs, vonoprazan still had a certain effect (Iwakiri et al., 2017).

Citation analysis is a statistical method of illustrating the quantity of cited studies. Generally, the more often a study is cited, the greater its impact. Co-citation is when two studies are cited by ≥1 study at the same time, which indicates how closely the two studies are related. The greater the number of studies cited simultaneously, the closer the relationship between the two (Jiang et al., 2024). Based on co-citation analysis, we can gain a deeper understanding of the research trends and hotspots that researchers in this field are concerned about. Therefore, we conducted a co-citation analysis (The top five cited references are shown in Table 6), and at the same time, we performed cluster analysis (Figure 6) and burst analysis (Table 7) on the cited literature. The top five cited references were all studies related to vonoprazan, published in 2015–2016. Two studies (Sakurai et al., 2015; Jenkins et al., 2015) conducted in healthy male subjects in 2015 demonstrated that vonoprazan had a rapid onset of action, good tolerability, and a faster and more sustained acid suppressive effect than PPIs. A 2016 study (Murakami et al., 2016) showed that vonoprazan had a higher first-line eradication rate compared to lansoprazole when added to first-line triple therapy for the treatment of Helicobacter pylori infection. In addition, a pharmacogenomics study in 2016 showed that the use of vonoprazan 20 mg twice daily was not affected by CYP2C19 genotype and was superior to esomeprazole in drug metabolism (Kagami et al., 2016).

Based on the clustering analysis of cited literature, we obtained a total of 19 clusters, The average Modularity Q value is 0.8834 (>0.3), and the average Silhouette S value is 0.9497 (>0.5), indicating that the clustering is reasonable (Sabé et al., 2024). We can roughly divide the 19 clustered words into several categories. #0 (helicobacter pylori), #2 (gastroesophageal reflux disease), #8 (eosinophilic esophagitis), #10 (peptic ulcer disease), #14 (gerd or gord) can be classified as ARDs, and based on the previous analysis, we can also classify research topics related to #7 (endoscopic submucosal dissection) as ARDs. It can be observed that research on Helicobacter pylori infection has been widely cited in recent years, and compared to other diseases, research on Helicobacter pylori infection remains a hot topic. #1 (dual therapy), #3 (amoxicillin), #5 (7-day triple therapy), #6 (tak-438), #11 (itopride), #12 (gelatine microsphere) and #17 (drug solubility) can be classified as therapeutic drugs or treatment regimens. Among them, research on dual therapy has been widely cited in recent years and has received higher attention compared to triple therapy. #4 (potassium channel), #9 (ATP), and #18 (h + - k + - ATPase) can be classified as research mechanisms, and they are earlier in the timeline. In addition, we also found some other clustering words: #13 (alginate), #15 (hypergastrinemia), #16 (small intestinal injury). The publications under these clustered words have been jointly cited over a period of time, and the studies that cited these publications specifically focused on the adverse reactions of hypergastrinemia caused by P-CABs (Sugano, 2018) and the potential protective effects of P-CABs on small intestine injury (Lim et al., 2012).

In the burst analysis, most of the studies were published between 2015 and 2016 on vonoprazan, which has already been introduced before, so we will not elaborate on the results. We would like to focus on reporting the last study in the table, which was published in 2018 and has been receiving attention since 2019. This article was a systematic review that mainly evaluated the efficacy of vonoprazan compared to PPIs, added to triple therapy, in treating patients with clarithromycin resistant Helicobacter pylori infection. The results demonstrated that vonoprazan was equally effective as traditional PPIs (Li et al., 2018).